We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is HeartSciences Inc. (HSCS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
HeartSciences Inc. is a member of our Medical group, which includes 916 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. HeartSciences Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for HSCS' full-year earnings has moved 0.8% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that HSCS has returned about 15.2% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 5.1% on average. This shows that HeartSciences Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is ImmunityBio (IBRX - Free Report) . The stock has returned 336.4% year-to-date.
For ImmunityBio, the consensus EPS estimate for the current year has increased 6.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, HeartSciences Inc. belongs to the Medical Info Systems industry, which includes 41 individual stocks and currently sits at #97 in the Zacks Industry Rank. This group has gained an average of 24.3% so far this year, so HSCS is slightly underperforming its industry in this area.
In contrast, ImmunityBio falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 449 stocks and is ranked #105. Since the beginning of the year, the industry has moved +5.7%.
HeartSciences Inc. and ImmunityBio could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is HeartSciences Inc. (HSCS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
HeartSciences Inc. is a member of our Medical group, which includes 916 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. HeartSciences Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for HSCS' full-year earnings has moved 0.8% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that HSCS has returned about 15.2% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 5.1% on average. This shows that HeartSciences Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is ImmunityBio (IBRX - Free Report) . The stock has returned 336.4% year-to-date.
For ImmunityBio, the consensus EPS estimate for the current year has increased 6.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, HeartSciences Inc. belongs to the Medical Info Systems industry, which includes 41 individual stocks and currently sits at #97 in the Zacks Industry Rank. This group has gained an average of 24.3% so far this year, so HSCS is slightly underperforming its industry in this area.
In contrast, ImmunityBio falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 449 stocks and is ranked #105. Since the beginning of the year, the industry has moved +5.7%.
HeartSciences Inc. and ImmunityBio could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.